Effect of co-infection with intestinal parasites on COVID-19 severity: A prospective observational cohort study. (September 2021)

• Record Type: Journal Article
• Authors: Wolday, Dawit; Gebrecherkos, Teklay; Arefaine, Zekarias Gessesse; Kiros, Yazezew Kebede; Gebreegzabher, Atsbeha; Tasew, Geremew; Abdulkader, Mahmud; Abraha, Hiluf Ebuy; Desta, Abraham Aregay; Hailu, Ataklti; Tollera, Getachew; Abdella, Saro; Tesema, Masresha; Abate, Ebba; Endarge, Kidist Lakew; Hundie, Tsegaye Gebreyes; Miteku, Frehiwot Kassahun; Urban, Britta C.; Schallig, Henk H.D.F.; Harris, Vanessa C.; de Wit, Tobias F. Rinke
• Is Part Of: EClinicalMedicine. Volume 39(2021)
• Publication Date: 2021-09
• Subjects: COVID-19 -- Severity -- parasite -- africa -- co-infection; Medicine -- Research -- Periodicals; Medical policy -- Periodicals; Clinical Medicine; Health Policy; Public Health; Medical policy; Medicine -- Research; Periodical; Electronic journals; Periodicals; 613
• DOI: 10.1016/j.eclinm.2021.101054
• Languages: English
• ISSNs: 2589-5370

Abstract

Abstract: Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection results in a spectrum of clinical presentations. Evidence from Africa indicates that significantly less COVID-19 patients suffer from serious symptoms than in the industrialized world. We and others previously postulated a partial explanation for this phenomenon, being a different, more activated immune system due to parasite infections. Here, we aimed to test this hypothesis by investigating a potential correlation of co-infection with parasites with COVID-19 severity in an endemic area in Africa. Methods: Ethiopian COVID-19 patients were enrolled and screened for intestinal parasites, between July 2020 and March 2021. The primary outcome was the proportion of patients with severe COVID-19. Ordinal logistic regression models were used to estimate the association between parasite infection, and COVID-19 severity. Models were adjusted for sex, age, residence, education level, occupation, body mass index, and comorbidities. Findings: 751 SARS-CoV-2 infected patients were enrolled, of whom 284 (37.8%) had intestinal parasitic infection. Only 27/255 (10.6%) severe COVID-19 patients were co-infected with intestinal parasites, while 257/496 (51.8%) non-severe COVID-19 patients were parasite positive ( p <0.0001). Patients co-infected with parasites had lower odds of developing severe COVID-19, with an adjusted odds ratio (aOR) of 0.23 (95% CI 0.17–0.30; p <0.0001) for all parasites, aOR 0.37 ([95% CI 0.26–0.51]; p <0.0001) for protozoa, and aOR 0.26 ([95% CI 0.19–0.35]; p <0.0001) for helminths. When stratified by species, co-infection with Entamoeba spp., Hymenolepis nana, Schistosoma mansoni, and Trichuris trichiura implied lower probability of developing severe COVID-19. There were 11 deaths (1.5%), and all were among patients without parasites ( p = 0.009). Interpretation: Parasite co-infection is associated with a reduced risk of severe COVID-19 in African patients. Parasite-driven immunomodulatory responses may mute hyper-inflammation associated with severe COVID-19. Funding: European and Developing Countries Clinical Trials Partnership (EDCTP) – European Union, and Joep Lange Institute (JLI), The Netherlands. Trial registration: Clinicaltrials.gov: NCT04473365